

Nasdaq: OKYO



Market Data

OKYO Pharma Ltd. Nasdaq: OKYO

Fiscal Year	Dec. 31
Price	\$1.04
Market Cap	\$35.2M
Shares Out.	33.8M
Float	24.5M
Avg. Vol. (90-day)	41,999
Cash (mrq)1	\$0.8M

Price & share data as of August 22, 2024

Auditor:

Forvis Mazars LLP

Legal Counsel:

Orrick, Herrington & Sutcliffe (UK) LLP

Transfer Agent:

Worldwide Stock Transfer, LLC

okyopharma.com

Company Overview

OKYO Pharma a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy. Leveraging a unique lipid-conjugated chemerin peptide, OKYO's lead candidate, OK-101, is designed to address inflammation and pain more effectively than current treatments. The recent Phase 2 trial for DED demonstrated notable improvements in both symptoms and signs within just 15 days, with a favorable safety profile and no drug-related serious adverse events. Moreover, OK-101 also offers a significant opportunity to treat the ocular disease called NCP, with no FDA approved drug to treat patients suffering from this acute, chronic, ocular condition. OKYO's robust patent protection through at least 2039, plus an experienced management team, with proven success in clinical development thru FDA approval, underscore its strong positioning for future growth in ophthalmology therapeutics.

Investment Highlights

Innovative pipeline targeting large, underserved markets with high unmet medical needs

- Lead candidate, OK-101, a novel lipid-conjugated chemerin peptide, targets two significant ocular conditions: Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP)
- DED is a multi-billion-dollar market with over 38 million affected individuals in the U.S. alone
- NCP represents an untapped market with no current FDA-approved treatments, offering substantial growth potential for OKYO
- Recent Phase 2 trial for OK-101 in DED showed significant improvements in both symptoms and signs as early as 15 days, with a strong safety profile and no drug-related serious adverse events
- Expect to launch Phase 2 trial for NCP in 3Q24

Strong intellectual property

 Patents provide protections through at least 2039 with potential extensions further enhancing competitive position

Experienced leadership with proven track record

- Extensive experience in drug development with history of successful drug commercialization
- CEO co-founded Synergy Pharmaceuticals and was instrumental in developing and securing FDA approval for Trulance®, a drug now marketed by Bausch Health
- CSO brings 30+ years of ophthalmic research and pharmaceutical R&D experience; authored 50+ peer-reviewed publications



Nasdaq: OKYO





* Craig JP et al. Ocul Surf. 2017; 15:276; **Market Scope 2023 Dry Eye Product Market Review; does not include OTC artificial tears and other Rx anti-inflammatory and tear stimulants

Value Proposition

OKYO is advancing its lead candidate, OK-101, a novel lipid-conjugated chemerin peptide, which targets both Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP), two significant areas of unmet medical need.

The recent Phase 2 trial for DED demonstrated rapid and notable improvements in symptoms and signs within just 15 days, coupled with a strong safety profile and no drug-related serious adverse events. With over 38 million people affected by DED in the U.S. alone, OK-101 could capture a substantial share of this multi-billion-dollar market upon approval. Additionally, the potential to address NCP, a condition with no FDA-approved therapies, opens a new market opportunity with significant growth potential. OKYO's robust intellectual property portfolio, which extends through at least 2039, further strengthens its competitive advantage.

The company is led by an experienced management team, with CEO Dr. Gary S. Jacob, who has over 35 years in the biopharma industry and has successfully guided a drug through FDA approval, and CSO Dr. Raj Patil, who brings 30 years of ophthalmic research expertise. Looking ahead, OKYO plans to initiate a Phase 2 trial for NCP in Q3 2024, providing multiple near-term catalysts for investors. This combination of a differentiated product candidate, significant market opportunities, and experienced leadership makes OKYO Pharma a compelling investment opportunity in the ophthalmology therapeutics space.

Pipeline

Indication	Pre-clinical	Phase 1	Phase 2	Phase 3
OK-101				
Dry Eye Disease ("DED")	Phase 2 Trial Completed	d		
Neuropathic Corneal Pain ("NCP")	Plan to open trial in Q3 2	2024		
Allergic Conjunctivitis				
Uveitis		•		

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy an are not purported to be complete. As such, the information should not be construed as a advice obtained sa advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or many and is not an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or the information provided, or for any direct, indirect, consequential incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information and social materials or the profits of the profits of the print of the print of the profits of the print of